Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis
ORR with ICI plus antiangiogenics was lower after prior ICI exposure, with substantial variability estimates among included trials, either due to differences among antiangiogenic agents used or trial-related factors. Future exploration of ICI combined with antiangiogenics in UC, especially in ICI-refractory setting, will benefit from better patient selection.
Authors
- Omar Alhalabi (ORCID: https://orcid.org/0000-0002-9658-2206)
- Matthew T. Campbell (ORCID: https://orcid.org/0000-0003-1915-4491)
- Ekaterina Proskuriakova (ORCID: https://orcid.org/0000-0003-2730-2271)
- Raed Benkhadra
- Iuliia Kovalenko (ORCID: https://orcid.org/0000-0003-4821-2195)
- Daniele Raggi (ORCID: https://orcid.org/0000-0002-4185-2475)
- Giuseppe Fallara (ORCID: https://orcid.org/0000-0001-7872-2650)
- Yimin Geng (ORCID: https://orcid.org/0000-0002-8491-3151)
- Pavlos Msaouel (ORCID: https://orcid.org/0000-0001-6505-8308)
- Emanuele Crupi (ORCID: https://orcid.org/0000-0002-3379-2644)
- Mohammad Jad Moussa (ORCID: https://orcid.org/0009-0000-7960-8614)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- Eastern Virginia Medical School (US)
- The University of Texas at San Antonio Health Science Center (US)
- Sinai Health System (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- Old Dominion University (US)
Publication Details
- Journal
- Bladder Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1177/23523735241296763
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15